These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34162282)

  • 1. The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best-worst scaling approach.
    Wranik WD; Székely RR; Mayer S; Hiligsmann M; Cheung KL
    J Med Econ; 2021; 24(1):846-856. PubMed ID: 34162282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.
    Feig C; Cheung KL; Hiligsmann M; Evers SMAA; Simon J; Mayer S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):223-232. PubMed ID: 28862060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOST IMPORTANT BARRIERS AND FACILITATORS REGARDING THE USE OF HEALTH TECHNOLOGY ASSESSMENT.
    Cheung KL; Evers SMAA; de Vries H; Hiligsmann M
    Int J Technol Assess Health Care; 2017 Jan; 33(2):183-191. PubMed ID: 28849758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of barriers and facilitators in the use of health technology assessment in Colombia.
    Dams F; Gonzalez Rodriguez JL; Cheung KL; Wijnen BFM; Hiligsmann M
    J Med Econ; 2018 May; 21(5):510-517. PubMed ID: 29513062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most important barriers and facilitators of HTA usage in decision-making in Europe.
    Cheung KL; Evers SMAA; De Vries H; Levy P; Pokhrel S; Jones T; Danner M; Wentlandt J; Knufinke L; Mayer S; Hiligsmann M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):297-304. PubMed ID: 29303374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts.
    Wranik WD; Jakubczyk M; Drachal K
    Value Health; 2020 Apr; 23(4):471-480. PubMed ID: 32327164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOCAL HEALTH TECHNOLOGY ASSESSMENT IN CANADA: CURRENT STATE AND NEXT STEPS.
    Martin J; Polisena J; Dendukuri N; Rhainds M; Sampietro-Colom L
    Int J Technol Assess Health Care; 2016 Jan; 32(3):175-80. PubMed ID: 27491840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and facilitators influencing ethical evaluation in health technology assessment.
    Assasi N; Schwartz L; Tarride JE; O'Reilly D; Goeree R
    Int J Technol Assess Health Care; 2015 Jan; 31(3):113-23. PubMed ID: 26179275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT AT NATIONAL LEVEL: A STUDY FROM IRAN.
    Yazdizadeh B; Shahmoradi S; Majdzadeh R; Doaee S; Bazyar M; Souresrafil A; Olyaeemanesh A
    Int J Technol Assess Health Care; 2016 Jan; 32(3):181-9. PubMed ID: 27524462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.
    Marks Y; Hoch JS; Heath A; Pechlivanoglou P
    Pharmacoeconomics; 2024 Jul; 42(7):783-795. PubMed ID: 38607519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies.
    Lee HY; Nguyen TT; Park S; Hoang VM; Kim WH
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
    Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders.
    Wranik WD; Skedgel C; Hu M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):59-69. PubMed ID: 30169973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact assessment of Iran's health technology assessment programme.
    Yazdizadeh B; Mohtasham F; Velayati A
    Health Res Policy Syst; 2018 Feb; 16(1):15. PubMed ID: 29471838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community views and perspectives on public engagement in health technology assessment decision making.
    Wortley S; Tong A; Howard K
    Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.
    Zemplényi A; Tachkov K; Balkanyi L; Németh B; Petykó ZI; Petrova G; Czech M; Dawoud D; Goettsch W; Gutierrez Ibarluzea I; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Savova A; Manova M; Tesar T; Zerovnik S; Kaló Z
    Front Public Health; 2023; 11():1088121. PubMed ID: 37181704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.
    Wasir R; Irawati S; Makady A; Postma M; Goettsch W; Feenstra T; Buskens E
    PLoS One; 2019; 14(11):e0225626. PubMed ID: 31774854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring facilitators and barriers to introducing health technology assessment: a systematic review.
    Suharlim C; Kumar R; Salim J; Mehra M; Gilmartin C; Amaris Caruso A; Castro H
    Int J Technol Assess Health Care; 2021 Dec; 38(1):e5. PubMed ID: 36317684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.